Why Are So Many Traders Betting Against the First Therapy for Peanut Allergies?
Short-sellers are convinced a company marketing the first approved biologic for treating peanut allergies in children and teenagers will fail. Here's why.
Aimmune Therapeutics
AIMT
AIMT
$16.61
-$0.39
-2.3%
Price as of May 29, 2020, 4:30 p.m. EDT
View Interactive AIMT Charts
Aimmune Therapeutics, Inc.
Interactive Chart
News & Analysis: Aimmune Therapeutics
Aimmune Therapeutics Inc (AIMT) Q1 2020 Earnings Call Transcript
AIMT earnings call for the period ending March 31, 2020.
Is Aimmune Therapeutics a Buy?
A recent drug approval, a competitor's setback, and a discounted stock price make Aimmune an intriguing investment.
A Tale of 2 Biotechs With Competing Peanut Allergy Treatments
DBV Technologies and Aimmune are at the finish line for developing novel therapies for treating peanut allergies, but each has its own twist.
Should You Buy These 4 Biotech Stocks With Recent Drug Approvals?
These companies scored recent drug approvals. It's worth looking into their stocks to see if they're a buy now.
Why Aimmune Therapeutics Shares Fell 23.3% in February
A risk management process slowed the launch of Aimmune’s first product.
Aimmune's Launch of Peanut Allergy Drug Will Take Time
A month after the drug's approval, Aimmune is still working on getting it to patients.
Aimmune Therapeutics Inc (AIMT) Q4 2019 Earnings Call Transcript
AIMT earnings call for the period ending December 31, 2019.
Aimmune Therapeutics Just Made History: Is It a Buy?
The food allergy specialist just landed its first approval.
What Aimmune's Peanut Allergy Drug Approval Means for the Rest of the Pipeline
The FDA’s approval sets the company off on the right path as it advances in the treatment of food allergies.
